Jan Peter Yska

Jan Peter Yska

Auto-generated profile, based on publicly available information

Jan Peter Yska

Department of Clinical Pharmacy and Clinical Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
JYJan Peter Yska
Jan Peter Yska
EREric N. van Roon
Eric N. van Roon
ABAnthonius de Boer
Anthonius de Boer
HLHubert G. M. Leufkens
Hubert G. M. Leufkens
BWBob Wilffert
Bob Wilffert
ALArief Lalmohamed
Arief Lalmohamed
Obesity is a growing problem worldwide. Since 1980, the obesity rate has more than doubled. The World Health Organization estimated that in 2014, more than 600 million adults were obese.1 Overweight status and obesity are linked with more deaths worldwide than underweight status. Raised body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) is a major risk factor for diseases such as cardiovascular diseases, diabetes mellitus (DM), musculoskeletal disorders (such as osteoarthritis), and some cancers.1 For inducing weight loss, bariatric surgery is more effective than pharmacotherapy or lifestyle interventions.2,3 Several bariatric procedures are available including laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion.2,3 Bariatric surgery is not only a weight reduction therapy, but also reduces obesity-related complications such as DM, hypertension, and hyperlipidemia.3,4 Improvement of comorbidities after bariatric surgery is shown by a reduction in use of medication.5-7

22 February 2013 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
JYJan Peter Yska
Jan Peter Yska
SLSusanne van der Linde
Susanne van der Linde
VTVéronique V. Tapper
Véronique V. Tapper
JAJan A. Apers
Jan A. Apers
MEMarloes Emous
Marloes Emous
EREric N. van Roon
Eric N. van Roon

1 April 2005 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
EREric N. van van Roon
Eric N. van van Roon
TJTim L Jansen
Tim L Jansen
MLM A F J van de Laar
M A F J van de Laar
Janssen MJanssen M
Janssen M
JYJ P Yska
J P Yska
JBJ R B J Brouwers
J R B J Brouwers
Background: Leflunomide is the prodrug of the disease modifying antirheumatic metabolite A77 1726. More than 50% of patients withdraw from leflunomide treatment within one year, mainly because of adverse drug reactions. Therapeutic drug monitoring of A77 1726 may be useful in predicting the efficacy of leflunomide treatment. Objective: To study the relation between A77 1726 steady state serum concentrations and disease activity using the 28 joint (DAS28) response. Methods: Outpatients with rheumatoid arthritis on a stable leflunomide dose for >4 months were included. DAS28 score and adverse drug reactions were recorded. Blood samples were taken for determination of A77 1726 concentrations. The primary end point was the relation of serum A77 1726 concentrations with DAS28 response category Results: Serum A77 1726 concentrations were determined in 52 patients. A receiver operating characteristic (ROC) curve showed an area under the curve (AUC) of 0.73 (95% confidence interval, 0.54 to 0.93) (p<0.05). The sensitivity exceeded 99% at concentrations below 16 mg/l. DAS28 values at the point of sampling showed no relation with A77 1726 concentrations (AUC of the ROC curve = 0.50 (0.33 to 0.67) (NS)). Conclusions: A77 1726 steady state serum concentrations show a relation with DAS28 response. Determination of serum A77 1726 concentrations in patients with insufficient response to treatment may help when decisions have to be made about continuation of treatment or dose adjustment.

27 March 2007 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
PVPeter H.J. van der Voort
Peter H.J. van der Voort
EBE. Christiaan Boerma
E. Christiaan Boerma
JYJan Peter Yska
Jan Peter Yska
To study the relation between serum and peritoneal levels of amphotericin B and flucytosine during intravenous treatment in patients with abdominal sepsis due to a perforated gut. Included were consecutive patients with abdominal sepsis due to a perforated gut, who were treated intravenously with amphotericin B and/or flucytosine after surgery if an abdominal drain was present. Amphotericin B and flucytosine were measured from simultaneously collected serum and abdominal fluid samples. Twenty-one consecutive patients were included. Five repeated samples were taken from three patients. The time interval between the start of the medication and the first sampling was median 4.0 days (range 2–7 days). The correlation coefficient (r2) between serum and peritoneal levels of amphotericin B was 0.79. In nine patients (43%) with a maximum serum level of 0.28 mg/L, amphotericin B in the peritoneal fluid was undetectable. The lowest serum level that was present with a detectable peritoneal level was 0.16 mg/L. A short duration of treatment (2 days) was associated with low serum and undetectable peritoneal levels. In seven patients, flucytosine levels were measured. Peritoneal flucytosine levels did not differ significantly from serum levels. Serum and peritoneal flucytosine levels correlated well with r2 = 0.88. Peritoneal amphotericin B level was inversely correlated with C-reactive protein level on the same day (r2 = 0.30). It is shown, during continuous infusion, that peritoneal levels of amphotericin B are lower than serum levels. The amphotericin B serum levels should exceed 0.5 mg/L to obtain peritoneal levels above MIC values. Flucytosine levels in the abdominal fluid are comparable to serum levels and within MIC ranges.

1 September 2004 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
EREric N. van van Roon
Eric N. van van Roon
JYJ.P. Yska
J.P. Yska
JRJ. Raemaekers
J. Raemaekers
TJTim L Jansen
Tim L Jansen
MWM. van Wanrooy
M. van Wanrooy
JBJ.R.B.J. Brouwers
J.R.B.J. Brouwers

3 November 2015 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JYJan Peter Yska
Jan Peter Yska
DMDouwe H. van der Meer
Douwe H. van der Meer
ADAlbert R. Dreijer
Albert R. Dreijer
WEWilleke Eilander
Willeke Eilander
JAJan A. Apers
Jan A. Apers
EREric N. van Roon
Eric N. van Roon